Dr Joanne Evans Consultant medical oncologist

Background

Jo Evans is a consultant in medical oncology at Imperial College Healthcare NHS Trust where she specialises in the treatment of all thoracic malignancies and as a cancer generalist, providing 'acute oncology' services. She holds an Honorary Senior Teaching Fellowship at the Institute of Cancer Research and an Honorary Senior Lectureship at Imperial College London.

A basic medical scientist by initial training, holding a first degree in genetics and a molecular biology-based DPhil, both awarded before reading medicine, with the intension of becoming an oncologist.

Her area of expertise as a molecular oncologist lies in lung cancers harbouring 'driver mutations'; including EGFR, ALK, BRAF V600, MET exon 14 skip, RET, NTRK, ROS1 and KRAS G12C mutations. She also has considerable expertise in delivering combination therapies across cytotoxic chemotherapy, immunotherapy and tyrosine kinase inhibitors across non-small cell lung cancers, small cell lung cancers, mesothelioma and thymic epithelial malignancies.

She has especially enjoying growing the lung themed clinical trials portfolio at the Trust, and has acted in the capacity of both local principle investigator, and chief investigator on both national and international trials. She also enjoys and values participating in research, working closely with several academic research groups, presenting work nationally and internationally. She also serves on the Scientific Advisory Board of ALK Positive.

She enjoys teaching and contributes to both undergraduate and postgraduate medical curriculum delivery. She is the lung cancer module lead for the Institute of Cancer Research’s MSc in oncology and has been an invited speaker for organisations such as Royal College of Physicians, Edinburgh, Royal College of Physicians, England and the British Thoracic Oncology Society.

Expertise

Lung cancers driven by specific mutations (EGFR, ALK, ROS1, BRAF V600, RET, NTRK, KRAS G12C, Met exon 14 skip); Non-small cell lung cancer; Small cell lung cancer, Mesothelioma, Thymic epithelial malignancies. Acute oncology.

Research & publications

Publications

Sharma, R., Alharbi, S., Ellum, K., Motedayen-Aval, L.,… …and Evans, J. 2025. Deep sequencing of circulating tumour DNA as a longitudinal biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma. npj Precision Oncology Accepted for publication

Korolewicz JA, Scheiner B, Fulgenzi CAM, D'Alessio A… Evans JS… et al., 2024. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden. CHEMOTHERAPY, Vol 69(4), Pages: 205-211

Cortellini A, Barrichello APC, Alessi JV, Ricciuti B, …Evans J… et al. 2022. A multicentre study of pembrolizumab time-of- day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions. ANNALS OF ONCOLOGY33(11), Pages 1202-1204

Evans JS, Beaumont J, Braga M, Masrour N, Mauri F,et al. 2022, Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy., Eur J Cancer, Vol: 176, Pages: 110-120

Cortellini A, Ricciuti B, Vaz VR, Soldato D… Evans JS… et al., 2022, Prognostic effect of body mass index in patients with advanced NSCLC treated with chemo-immunotherapy combinations, Journal for ImmunoTherapy of Cancer, Vol: 10, Pages: 1-10, ISSN: 2051-1426

Sharma R, Slater S, Evans J, Martinez M, Ward C, et al, 2022, ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs), BMC CANCER, Vol: 22

Pinato DJ, Tabernero J, Bower M, Scotti L… Evans JS… et al. 2021, Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study., The Lancet. Oncology, Vol: 22, Pages: 1669-1680, ISSN: 1470-2045

Pinato DJ, Tabernero J, Bower M, Scotti L… Evans JS… et al., 2021, Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study, LANCET ONCOLOGY, Vol: 22, Pages: 1669-1680, ISSN: 1470-2045

Pinato DJ, Patel M, Scotti L, Colomba E… Evans JS… et al. 2021, Time-Dependent COVID-19 Mortality in Patients With Cancer An Updated Analysis of the OnCovid Registry, JAMA ONCOLOGY, Vol: 8, Pages: 114-122, ISSN: 2374-2437

Abdelmalak R, Lythgoe MP, Evans J, Flynn M, Waters J, et al. 2021, Exploration of novel prognostic markers in grade 3 neuroendocrine neoplasia, Cancers, Vol: 13, Pages: 1-12, ISSN: 2072-6694

Pinato DJ, Scotti L, Gennari A, Colomba-Blameble E… Evans JS…et al. 2021, Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study, EUROPEAN JOURNAL OF CANCER, Vol: 150, Pages: 190-202, ISSN: 0959-8049

Pinato D, Zambelli A, Aguilar-Company J, Bower M… Evans J… 2020, Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients, Cancer Discovery, Vol: 10, Pages: 1465-1474, ISSN: 2159-8274

Pinato DJ, Lee AJX, Biello F, Seguí E… Evans JS…et al. 2020, Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe, Cancers, Vol: 12, ISSN: 2072-6694

Pinato DJ, Vallipuram A, Evans JS, Wong C, Zhang H, et al. 2020, Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours, Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships, Vol: 111, Pages: 465-474, ISSN: 0028-3835

Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, et al., 2019, 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine t

Private practice

Visit the Imperial College Healthcare Private care website